Asma, patogenia y nuevos tratamientos

1 Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59: 469 -78.
2 WHO. Global surveillance, prevention and control of chronic respiratory diseases: a comprehensive approach. 2007. www.who.int/gard/publications/GARD%20Book%202007.pdf .
3 Suissa S, Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol 2001; 107: 937 -44.
4 Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343: 332 -6.
5 Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med 2006; 355: 2226 -35.
6 Pearce N, AïtKhaled N, Beasley R, Mallol J, Keil U, Mitchell E; the ISAAC Phase Three Study Group. Worldwide variations in the prevalence of asthma symptoms: the International Study of Asthma and Allergies in Childhood (ISAAC). Eur Respir J 1998 ; 12: 315 -35.
7 Akinbami LJ, Moorman JE, Bailey C, Zahran HS, King M, Johnson CA, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010.  NCHS Data Brief 2012; 94: 1 -8.
8 Kausel L, Boneberger A, Calvo M, Radon K. Childhood asthma and allergies in urban, semiurban, and rural residential sectors in Chile. Scientific World Journal 2013 ; 2013: 937935.
9 Vital signs: asthma prevalence, disease characteristics, and self-management education: United States, 2001-2009.  MMWR Morb Mortal Wkly Rep 2011; 60: 547 -52.
10 Von Mutius E, Martinez FD, Fritzsch C, Nicolai T, Roell G, Thiemann HH. Prevalence of asthma and atopy in two areas o1f West and East Germany.  Am J Respir Crit Care Med 1994; 149: 358 -64.
11 Nicolai T, Carr D, Weiland SK, Duhme H, von Ehrenstein O, Wagner C, et al. Urban traffic and pollutant exposure related to respiratory outcomes and atopy in a large sample of children. Eur Respir J 2003; 21: 956 -63.
12 Clark NA, Demers PA, Karr CJ, Koehoorn M, Lencar C, Tamburic L, et al. Effect of early life exposure to air pollution on development of childhood asthma.  Environ Health Perspect 2010; 118: 284 -90.
13 Strachan DP, Cook DG. Health effects of passive smoking. 6. Parental
smoking and childhood asthma: longitudinal and case-control studies. Thorax 1998; 53: 204 -12.
14 Camargo CA Jr, Weiss ST, Zhang S, Willett WC, Speizer FE. Prospective study of body mass index, weight change, and risk of adult-onset asthma in women. Arch Intern Med 1999; 159: 2582 -8.
15 Ege MJ, Mayer M, Normand AC, Genuneit J, Cookson WO, Braun-Fahrlander C, et al. Exposure to environmental microorganisms and childhood asthma. N Engl J Med 2011 ; 364: 701 -9.
16 Custovic A, Rothers J, Stern D, Simpson A, Woodcock A, Wright AL, et al. Effect of day care attendance on sensitization and atopic wheezing differs by Toll-like receptor 2 genotype in 2 population-based birth cohort studies. J Allergy Clin Immunol 2011; 127 : 390 -97 e1-9.
17 Erkkola M, Nwaru BI, Kaila M, Kronberg-Kippila C, Ilonen J, Simell O, et al. Risk of asthma and allergic outcomes in the offspring in relation to maternal food consumption during pregnancy: a Finnish birth cohort study. Pediatr Allergy Immunol 2012; 23: 186 -94.
18 Nwaru BI, Takkinen HM, Niemela O, Kaila M, Erkkola M, Ahonen S, et al. Timing of infant feeding in relation to childhood asthma and allergic diseases. J Allergy Clin Immunol 2013; 131: 78 -86.
19 Pearce N, Ait-Khaled N, Beasley R, Mallol J, Keil U, Mitchell E, et al. Worldwide trends in the prevalence of asthma symptoms: phase III of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax 2007; 62: 758 -66.
8 of 11
20 Sullivan PW, Ghushchyan VH, Slejko JF, Belozeroff V, Globe DR, Lin SL. The burden of adult asthma in the United States: evidence from the Medical Expenditure Panel Survey. J Allergy Clin Immunol 2011; 127: 363 -69 e1-3.
21 Bonilla S, Kehl S, Kwong KY, Morphew T, Kachru R, Jones CA. School absenteeism in children with asthma in a Los Angeles inner city school. J
Pediatr 2005; 147: 802 -6.
22 Silverstein MD, Mair JE, Katusic SK, Wollan PC, O’Connell EJ, Yunginger JW. School attendance and school performance: a population-based study of children with asthma. J Pediatr 2001; 139: 278 -83.
23 Barnett SB, Nurmagambetov TA. Costs of asthma in the United States: 2002-2007.  J Allergy Clin Immunol 2011; 127: 145 -52.
24 Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343 -73.
25 Carolan BJ, Sutherland ER. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: recent advances. J Allergy Clin Immunol 2013; 131: 627 -34; quiz 35.
26 Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012; 18: 716 -25.
27 Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet 2006; 368: 804 -13.
28 Fitzpatrick AM, Teague WG, Meyers DA, Peters SP, Li X, Li H, et al. Heterogeneity of severe asthma in childhood: confirmation by cluster analysis of children in the National Institutes of Health/National Heart, Lung, and Blood Institute Severe Asthma Research Program. J Allergy Clin Immunol 2011; 127: 382 -89 e1-13.
29 Chang TS, Lemanske RF Jr, Mauger DT, Fitzpatrick AM, Sorkness CA, Szefler SJ, et al. Childhood asthma clusters and response to therapy in clinical trials. J Allergy Clin Immunol 2014; 133: 363 -9
30 Duffy DL, Martin NG, Battistutta D, Hopper JL, Math ews JD. Genetics of asthma and hay fever in Australian twins. Am Rev Respir Dis 1990; 142: 1351 -8.
31 Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzi gon E, Heath S, et al. A large-scale, consortium-based genomewide association study of asthma. N Engl J Med 2010; 363: 1211 -21.
32 Brand S, Kesper DA, Teich R, Kilic-Niebergall E, Pinkenburg O, Bothur E, et al. DNA methylation of TH1/TH2 cytokine genes affects sensitization and progress of experimental asthma. J Allergy Clin Immunol 2012; 129: 1602 -10 e6.
33 Perera F, Tang WY, Herbstman J, Tang D, Levin L, M iller R, et al. Relation of DNA methylation of 5’-CpG island of ACSL3 to transplacental exposure to airborne polycyclic aromatic hydrocarbons and childhood asthma. PLoS One 2009; 4: e4488 .
34 Joubert BR, Haberg SE, Nilsen RM, Wang X, Vollset S E, Murphy SK, et al. 450K epigenome-wide scan identifies differential DNA methylation in newborns related to maternal smoking during pregnancy.  Environ Health Perspect 2012; 120: 1425 -31.
35 Szabo SM, Levy AR, Gooch KL, Bradt P, Wijaya H, Mi tchell I. Elevated risk of asthma after hospitalization for respiratory syncytial virus infection in infancy. Paediatr Respir Rev 2013; 13 (suppl 2): S9 -15.
36 Navarro S, Cossalter G, Chiavaroli C, Kanda A, Fleu ry S, Lazzari A, et al. The oral administration of bacterial extracts prevents asthma via the recruitment of regulatory T cells to the airways. Mucosal Immunol 2011; 4: 53 -65.
37 Salazar F, Ghaemmaghami AM. Allergen recognition b y innate immune cells: critical role of dendritic and epithelial cells. Front Immunol 2013; 4: 356. 38 Lambrecht BN, Hammad H. The airway epithelium in as thma. Nat Med 2012; 18: 684 -92.
39 Kallal LE, Schaller MA, Lindell DM, Lira SA, Lukacs  NW. CCL20/CCR6 blockade enhances immunity to RSV by impairing recruitment of DC. Eur J Immunol 2010; 40: 1042 -52.
40 Pichavant M, Charbonnier AS, Taront S, Brichet A, W allaert B, Pestel J, et al. Asthmatic bronchial epithelium activated by the proteolytic allergen Der p 1 increases selective dendritic cell recruitment. J Allergy Clin Immunol 2005; 115 : 771 -8.
41 Lambrecht BN, Hammad H. Lung dendritic cells in respiratory viral infection and asthma: from protection to immunopathology.  Annu Rev Immunol 2012; 30: 243 -70.
42 Hammad H, Lambrecht BN. Lung dendritic cell migration. Adv Immunol 2007; 93: 265 -78.
43 Otero K, Vecchi A, Hirsch E, Kearley J, Vermi W, De l Prete A, et al. Nonredundant role of CCRL2 in lung dendritic cell trafficking. Blood 2010; 116: 2942 -9.
44 Maazi H, Lam J, Lombardi V, Akbari O. Role of plas macytoid dendritic cell subsets in allergic asthma. Allergy 2013; 68: 695 -701.
45 Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans  J, Bentley AM, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326: 298 -304.
46 Oh CK, Geba GP, Molfino N. Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev
47 Schoenborn JR, Wilson CB. Regulation of interferon- gamma during innate and adaptive immune responses. Adv Immunol 2007; 96: 41 -101.
48 Cosmi L, Liotta F, Maggi E, Romagnani S, Annunziat o F. Th17 cells: new players in asthma pathogenesis. Allergy 2011; 66: 989 -98.
49 Wilson RH, Whitehead GS, Nakano H, Free ME, Kolls JK, Cook DN. Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness. Am J Respir Crit Care Med 2009; 180: 720 -30.
50 Lloyd CM, Saglani S. T cells in asthma: influences  of genetics, environment, and T-cell plasticity. J Allergy Clin Immunol 2013; 13 : 1267 -74; quiz 75.
51 O’Hehir RE, Gardner LM, de Leon MP, Hales BJ, Bion do M, Douglass JA, et al. House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells. Am J Respir Crit Care Med 2009; 180: 936 -47.
52 Bacharier LB, Jabara H, Geha RS. Molecular mechani sms of immunoglobulin E regulation. Int Arch Allergy Immunol 1998; 115: 257 -69.
53 Saenz SA, Siracusa MC, Perrigoue JG, Spencer SP, Urban JF Jr, Tocker JE, et al. IL25 elicits a multipotent progenitor cell population that promotes T(H)2 cytokine responses. Nature 2010; 464: 1362 -6.
54 Her E, Frazer J, Austen KF, Owen WF Jr. Eosinophil hematopoietins antagonize the programmed cell death of eosinophils. Cytokine and glucocorticoid effects on eosinophils maintained by endothelial cell-conditioned medium. J Clin Invest 1991; 88 : 1982 -7.
55 Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov 2013; 12: 117 -29.
56 Zimmermann N, McBride ML, Yamada Y, Hudson SA, Jone s C, Cromie KD, et al. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. Allergy 2008; 63: 1156 -63.
57 Nutku E, Aizawa H, Hudson SA, Bochner BS. Ligation  of Siglec-8: a selective mechanism for induction of human eosinophil apoptosis. Blood  2003; 101: 5014 -20.
58 Kita H. Eosinophils: multifunctional and distinctive properties. Int Arch Allergy Immunol 2013; 161 (suppl 2):3 -9.
59 Hogan SP, Rosenberg HF, Moqbel R, Phipps S, Foster PS, Lacy P, et al. Eosinophils: biological properties and role in health and disease. Clin Exp Allergy 2008; 38: 709 -50.
60 Reber L, Da Silva CA, Frossard N. Stem cell factor a nd its receptor c-Kit as targets for inflammatory diseases. Eur J Pharmacol 2006; 533: 327 -40
61 Barnes PJ. Pathophysiology of allergic inflammation . Immunol Rev 2011; 242: 31 -50.
62 Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ. Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 1999; 160: 1532 -9.
63 Kato T, Takeda Y, Nakada T, Sendo F. Inhibition by dexamethasone of human neutrophil apoptosis in vitro. Nat Immun 1995; 14: 198 -208.
64 Cox G. Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 1995; 154: 4719 -25.
65 Ordonez CL, Shaughnessy TE, Matthay MA, Fahy JV. Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma: clinical and biologic significance. Am J Respir Crit Care Med 2000; 161: 1185 -90.
66 Jeffery PK. Remodeling in asthma and chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164: S28 -38.
67 Wadsworth B, Yang J, Dorscheid D. IL-13, asthma, and glycosylation in airway epithelial repair. In: Chang C, ed. Carbohydrates—comprehensive studies on glycobiology and glycotechnology. InTech, 2012.
68 Jeffery PK, Wardlaw AJ, Nelson FC, Collins JV, Kay AB. Bronchial biopsies in asthma. An ultrastructural, quantitative study and correlation with hyperreactivity. Am Rev Respir Dis 1989; 140: 1745 -53.
69 Montefort S, Roche WR, Holgate ST. Bronchial epithelial shedding in asthmatics and non-asthmatics. Respir Med 1993; 87 (suppl B): 9 -11.
70 Xiao C, Puddicombe SM, Field S, Haywood J, Broughton-Head V, Puxeddu I, et al. Defective epithelial barrier function in asthma. J Allergy Clin Immunol 2011; 128 : 549 -56 e1-12.
71 Erjefalt JS, Persson CG. Airway epithelial repair: breathtakingly quick and multipotentially pathogenic. Thorax 1997; 52 : 1010 -2.
72 Holgate ST, Davies DE, Lackie PM, Wilson SJ, Puddicombe SM, Lordan JL. Epithelial-mesenchymal interactions in the pathogenesis of asthma. J Allergy Clin Immunol 2000; 105: 193 -204.
73 Puddicombe SM, Polosa R, Richter A, Krishna MT, Howarth PH, Holgate ST, et al. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. FASEB J 2000; 14: 1362 -74.
74 Gizycki MJ, Adelroth E, Rogers AV, O’Byrne PM, Jeffery PK. Myofibroblast involvement in the allergen-induced late response in mild atopic asthma.  Am J Respir Cell Mol Biol 1997; 16: 664 -73.
75 Bossley CJ, Fleming L, Gupta A, Regamey N, Frith J, Oates T, et al. Pediatric severe asthma is characterized by eosinophilia and remodeling without T(H)2 cytokines. J Allergy Clin Immunol 2012; 129 : 974 -82 e13.
76 Sonnappa S, Bastardo CM, Saglani S, Bush A, Aurora P. Relationship between past airway pathology and current lung function in preschool between past airway pathology and current lung function in preschool wheezers. Eur Respir J 2011; 38: 1431 -6.
77 Gelb AF, Zamel N. Unsuspected pseudophysiologic emphysema in chronic persistent asthma. Am J Respir Crit Care Med 2000; 162: 1778 -82.
78 Grainge CL, Lau LC, Ward JA, Dulay V, Lahiff G, Wilson S, et al. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med
2011; 364: 2006 -15.
79 Doeing DC, Solway J. Airway smooth muscle in the pathophysiology and treatment of asthma. J Appl Physiol (1985) 2013; 114: 834 -43.
80 Hirst SJ, Barnes PJ, Twort CH. PDGF isoform-induced proliferation and receptor expression in human cultured airway smooth muscle cells. Am J Physiol 1996; 270 (3 Pt 1): L415 -28.
81 Cohen P, Rajah R, Rosenbloom J, Herrick DJ. IGFBP-3 mediates TGF-beta1-induced cell growth in human airway smooth muscle cells. Am J Physiol Lung Cell Mol Physiol 2000; 278: L545 -51.
82 Cohn L, Homer RJ, Marinov A, Rankin J, Bottomly K. Induction of airway mucus production by T helper 2 (Th2) cells: a critical role for interleukin 4 in cell recruitment but not mucus production. J Exp Med 1997; 186: 1737 -47.
83 Lee JJ, McGarry MP, Farmer SC, Denzler KL, Larson KA, Carrigan PE, et al. Interleukin-5 expression in the lung epithelium of transgenic mice leads to pulmonary changes pathognomonic of asthma. J Exp Med 1997;185: 2143 -56.
84 Tyner JW, Kim EY, Ide K, Pelletier MR, Roswit WT, Morton JD, et al. Blocking airway mucous cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferentiation signals. J Clin Invest 2006; 116: 309 -21.
85 Patel AC, Brett TJ, Holtzman MJ. The role of CLCA proteins in inflammatory airway disease. Annu Rev Physiol 2009; 71: 425 -49.
86 Expert Panel Report 3 (EPR-3). Guidelines for the diagnosis and management of asthma-summary report 2007. J Allergy Clin Immunol 2007; 120 (5 suppl): S94 -138.
87 From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2014. http://www.ginasthma.org/ .
88 Lemanske RF Jr, Mauger DT, Sorkness CA, Jackson DJ, Boehmer SJ, Martinez FD, et al. Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids. N Engl J Med 2010; 362: 975 -85.
89 Joos S, Miksch A, Szecsenyi J, Wieseler B, Grouven U, Kaiser T, et al. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: a systematic review. Thorax 2008; 63: 453 -62.
90 Peters SP, Kunselman SJ, Icitovic N, Moore WC, Pascual R, Ameredes BT, et al. Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 2010; 363: 1715 -26.
91 Kerstjens HA, Engel M, Dahl R, Paggiaro P, Beck E, Vandewalker M, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 2012; 367: 1198 -207.
92 Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; 1: CD003559.
93 Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, et al. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal. Pharmacoeconomics 2012; 30 : 991 -1004.
94 Cox PG, Miller J, Mitzner W, Leff AR. Radiofrequency ablation of airway smooth muscle for sustained treatment of asthma: preliminary investigations. Eur Respir J 2004; 24: 659 -63.
95 Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, et al. Asthma control during the year after bronchial thermoplasty. N Engl J Med 2007; 356: 1327 -37.
96 Wechsler ME, Laviolette M, Rubin AS, Fiterman J, Lapa e Silva JR, Shah PL, et al. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol 2013; 132: 1295 -302.
97 Martinez FD. New insights into the natural history of asthma: primary prevention on the horizon. J Allergy Clin Immunol 2011; 128: 939 -45.
98 Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehm er SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354: 1985 -97.
99 Warner SM, Knight DA. Airway modeling and remodeling in the pathogenesis of asthma. Curr Opin Allergy Clin Immunol 2008; 8: 44 -8.
100 Saglani S, Lui S, Ullmann N, Campbell GA, Sherburn  RT, Mathie SA, et al. IL-33 promotes airway remodeling in pediatric patients with severe steroid-resistant asthma. J Allergy Clin Immunol 2013; 132: 676 -85 e13.
101 Rabe KF, Vermeire PA, Soriano JB, Maier WC. Clinica l management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16: 802 -7.
102 Partridge MR, van der Molen T, Myrseth SE, Busse W W. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulmon Med 2006; 6: 13.
103 Wenzel SE, Busse WW. Severe asthma: lessons from t he severe asthma research program.  J Allergy Clin Immunol 2007; 119: 14 -21; quiz 22-3.
104 Serra-Batlles J, Plaza V, Morejon E, Comella A, Bru gues J. Costs of asthma according to the degree of severity. Eur Respir J 1998; 12: 1322 -6.
105 Bosley CM, Parry DT, Cochrane GM. Patient compliance with inhaled medication: does combining beta-agonists with corticosteroids improve compliance? Eur Respir J 1994; 7: 504 -9.
106 Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, et al. Effect of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012; 367: 904 -12.
107 Lipworth BJ. Systemic adverse effects of inhaled c orticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999; 159: 941 -55.
108 Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006 ; 129: 15 -26.
109 Philip G, Hustad C, Noonan G, Malice MP, Ezekowitz A, Reiss TF, et al. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol 2009; 124: 691 -6 e6
110 Philip G, Hustad CM, Malice MP, Noonan G, Ezekowit z A, Reiss TF, et al. Analysis of behavior-related adverse experiences in clinical trials of montelukast. J Allergy Clin Immunol 2009; 124: 699 -706 e8.
111 LaForce C, Korenblat P, Osborne P, Dong F, Higgins M. 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol. Curr Med Res Opin 2009; 25: 2353 -9.
112 Pearlman DS, Greos L, LaForce C, Orevillo CJ, Owen R, Higgins M. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma. Ann Allergy Asthma Immunol 2008; 101: 90 -5.
113 Woodcock A, Bleecker ER, Lotvall J, O’Byrne PM, Bateman ED, Medley H, et al. Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. Chest 2013; 144: 1222 -9.
114 Reber LL, Daubeuf F, Plantinga M, De Cauwer L, Ger lo S, Waelput W, et al. A dissociated glucocorticoid receptor modulator reduces airway hyperresponsiveness and inflammation in a mouse model of asthma. J Immunol 2012; 188: 3478 -87.
115 Barnes PJ, Adcock IM. Glucocorticoid resistance in inflammatory diseases. Lancet 2009; 373: 1905 -17.
116 Zhang Y, Leung DY, Goleva E. Anti-inflammatory and corticosteroid-enhancing actions of vitamin D in monocytes of patients with steroid-resistant and those with steroid-sensitive asthma. J Allergy Clin Immunol 2014; 133: 1744 -52.e1.
117 Lai CK, Ho AS, Chan CH, Tang J, Leung JC, Lai KN. Interleukin-5 messenger RNA expression in peripheral blood CD4+ cells in asthma. J Allergy Clin Immunol 1996; 97: 1320 -8.
118 Hamid Q, Azzawi M, Ying S, Moqbel R, Wardlaw AJ, Corrigan CJ, et al. Expression of mRNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991; 87: 1541 -6.
119 Ying S, Durham SR, Corrigan CJ, Hamid Q, Kay AB. Ph enotype of cells expressing mRNA for TH2-type (interleukin 4 and interleukin 5) and TH1-type (interleukin 2 and interferon gamma) cytokines in bronchoalveolar lavage and bronchial biopsies from atopic asthmatic and normal control subjects. Am J Respir Cell Mol Biol 1995; 12: 477 -87.
120 Sakuishi K, Oki S, Araki M, Porcelli SA, Miyake S, Yamamura T. Invariant NKT cells biased for IL-5 production act as crucial regulators of inflammation. J Immunol 2007; 179: 3452 -62.
121 Dubucquoi S, Desreumaux P, Janin A, Klein O, Goldma n M, Tavernier J, et al. Interleukin 5 synthesis by eosinophils: association with granules and immunoglobulin-dependent secretion. J Exp Med 1994; 179: 703 -8.
122 Phillips C, Coward WR, Pritchard DI, Hewitt CR. Basophils express a type 2 cytokine profile on exposure to proteases from helminths and house dust mites. J Leukoc Biol 2003; 73: 165 -71.
123  Sehmi R, Wood LJ, Watson R, Foley R, Hamid Q, O’Byr ne PM, et al. Allergen-induced increases in IL-5 receptor alpha-subunit expression on bone marrow-derived CD34+ cells from asthmatic subjects. A novel marker of progenitor cell commitment towards eosinophilic differentiation. J Clin Invest 1997; 100: 2466 -75.
124 Molfino NA, Gossage D, Kolbeck R, Parker JM, Geba G P. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor.  Clin Exp Allergy 2012; 42: 712 -37.
125 Sitkauskiene B, Johansson AK, Sergejeva S, Lundin S, Sjostrand M, Lotvall J. Regulation of bone marrow and airway CD34+ eosinophils by interleukin-5. Am J Respir Cell Mol Biol 2004; 30: 367 -78.
126 Johansson AK, Sergejeva S, Sjostrand M, Lee JJ, Lotvall J. Allergen-induced traffic of bone marrow eosinophils, neutrophils and lymphocytes to airways. Eur J Immunol 2004 ; 34: 3135 -45.
127 Ochiai K, Kagami M, Matsumura R, Tomioka H. IL-5 but not interferon-gamma (IFN-gamma) inhibits eosinophil apoptosis by up-regulation of bcl-2 expression. Clin Exp Immunol 1997; 107: 198 -204.
128 Gauvreau GM, Ellis AK, Denburg JA. Haemopoietic processes in allergic disease: eosinophil/basophil development.  Clin Exp Allergy 2009; 39: 1297 -306.
129 Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor B J, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000; 356: 2144 -8.
130 Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 2007; 176: 1062 -71.
131  Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009; 360: 973 -84.
132  Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009; 360: 985 -93.
133 Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 2012; 380: 651 -9.
134  Castro M, Mathur S, Hargreave F, Boulet LP, Xie F, Young J, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011; 184: 1125 -32.
135  Busse WW, Katial R, Gossage D, Sari S, Wang B, Kolbeck R, et al. Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. J Allergy Clin Immunol 2010 ; 125: 1237 -44.e2.
136 Laviolette M, Gossage DL, Gauvreau G, Leigh R, Olivenstein R, Katial R, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol 2013; 132: 1086 -96.e5.
137 Fish SC, Donaldson DD, Goldman SJ, Williams CM, Kasaian MT. IgE generation and mast cell effector function in mice deficient in IL-4 and37  Fish SC, Donaldson DD, Goldman SJ, Williams CM, Kasaian MT. IgE generation and mast cell effector function in mice deficient in IL-4 and IL-13. J Immunol 2005; 174: 7716 -24.
138  Kroegel C, Julius P, Matthys H, Virchow JC Jr, Luttmann W. Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur Respir J 1996; 9: 899 -904.
139 Bradding P. The role of the mast cell in asthma: a reassessment. Curr Opin Allergy Clin Immunol 2003; 3: 45 -50.
140 Huang SK, Xiao HQ, Kleine-Tebbe J, Paciotti G, Marsh DG, Lichtenstein LM, et al. IL-13 expression at the sites of allergen challenge in patients with asthma.  J Immunol 1995; 155: 2688 -94.
141 Burd PR, Thompson WC, Max EE, Mills FC. Activated mast cells produce interleukin 13. J Exp Med 1995; 181: 1373 -80.
142 Schmid-Grendelmeier P, Altznauer F, Fischer B, Bizer C, Straumann A, Menz G, et al. Eosinophils express functional IL-13 in eosinophilic inflammatory diseases. J Immunol 2002; 169: 1021 -7.
143 Li H, Sim TC, Alam R. IL-13 released by and localized in human basophils. J Immunol 1996; 156: 4833 -8.
144 Mueller TD, Zhang JL, Sebald W, Duschl A. Structure, binding, and antagonists in the IL-4/IL-13 receptor system.  Biochim Biophys Acta  2002 ; 1592: 237 -50.
145 Goebeler M, Schnarr B, Toksoy A, Kunz M, Brocker EB, Duschl A, et al. Interleukin-13 selectively induces monocyte chemoattractant protein-1 synthesis and secretion by human endothelial cells. Involvement of IL-4R alpha and Stat6 phosphorylation. Immunology 1997; 91: 450 -7.
146 Li-Weber M, Krammer PH. Regulation of IL4 gene expression by T cells and therapeutic perspectives. Nat Rev Immunol  2003; 3: 534 -43.
147 Hershey GK. IL-13 receptors and signaling pathways: an evolving web. J Allergy Clin Immunol 2003; 111: 677 -90; quiz 91.
148 Borish LC, Nelson HS, Lanz MJ, Claussen L, Whitmore JB, Agosti JM, et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am J Respir Crit Care Med  1999; 160: 1816 -23.
149 Borish LC, Nelson HS, Corren J, Bensch G, Busse WW, Whitmore JB, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107: 963 -70.
150 Corren J, Busse W, Meltzer EO, Mansfield L, Bensch G, Fahrenholz J, et al. A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma.  Am J Respir Crit Care Med  2010; 181: 788 -96.
151 Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013; 368: 2455 -66.
152 Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011; 365: 1088 -98.
153 Morishima Y, Ano S, Ishii Y, Ohtsuka S, Matsuyama M, Kawaguchi M, et al. Th17-associated cytokines as a therapeutic target for steroid-insensitive asthma. Clin Dev Immunol 2013; 2013: 609395.
154 Bullens DM, Truyen E, Coteur L, Dilissen E, Hellings PW, Dupont LJ, et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir Res 2006; 7: 135.
155 Agache I, Ciobanu C, Agache C, Anghel M. Increased serum IL-17 is an independent risk factor for severe asthma. Respir Med 2010; 104: 1131 -7.
156 Molet S, Hamid Q, Davoine F, Nutku E, Taha R, Page N, et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001; 108: 430 -8.
157 Busse WW, Holgate S, Kerwin E, Chon Y, Feng J, Lin J, et al. Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. Am J Respir Crit Care Med 2013 ; 188: 1294 -302.
158 Barnes PJ. New drugs for asthma. Semin Respir Crit Care Med 2012; 33: 685 -94.
159 Gauvreau GM, Boulet LP, Cockcroft DW, Baatjes A, Cote J, Deschesnes F, et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008; 177: 952-8
160 Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni P, et al. SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects. Eur Respir J 2010; 35: 564 -70.
161 Beeh KM, Kanniess F, Wagner F, Schilder C, Naudts I, Hammann-Haenni A, et al. The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol 2013; 131: 866 -74.
162 Guntur VP, Reinero CR. The potential use of tyrosine kinase inhibitors in severe asthma. Curr Opin Allergy Clin Immunol 2012; 12 : 68 -75.
163 Hanania NA, Wenzel S, Rosen K, Hsieh HJ, Mosesova S, Choy DF, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187: 804 -11.
164 Perez-de-Llano LA, Carballada F, Castro Anon O, Pizarro M, Golpe R, Baloira A, et al. Exhaled nitric oxide predicts control in patients with difficult-to-treat asthma. Eur Respir J 2010; 35: 1221 -7.
165 Peters MC, Mekonnen ZK, Yuan S, Bhakta NR, Woodruff PG, Fahy JV. Measures of gene expression in sputum cells can identify T2-high and T2-low subtypes of asthma. J Allergy Clin Immunol 2014; 133: 388 -94.
166 Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364: 1505 -12.
167 Slager RE, Otulana BA, Hawkins GA, Yen YP, Peters SP, Wenzel SE, et al. IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. J Allergy Clin Immunol 2012; 130: 516 -22.e4.
168 Wechsler ME, Kunselman SJ, Chinchilli VM, Bleecker E, Boushey HA, Calhoun WJ, et al. Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial. Lancet  2009; 374: 1754 -64.
169 Adamko DJ, Sykes BD, Rowe BH. The metabolomics of asthma: novel diagnostic potential. Chest 2012; 141: 1295 -302.
170 Shaw DE, Berry MA, Thomas M, Green RH, Brightling CE, Wardlaw AJ, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial.  Am J Respir Crit Care Med 2007; 176: 231 -7.
171 Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial.  Lancet 2002; 360: 1715 -21.